— Researchers first identified and then used CRISPR to delete an enhancer located at +32 kb of the Irf8 transcriptional start site in mice. Knocking out this enhancer revealed that interferon regulatory factor 8 (IRF8) is required for the development of classical type 1 dendritic cells (cDC1s) but not…
— Technology Description
In search of more effective cancer treatments, inventors in Dr. Xiaowei Wang’s lab at Washington University School of Medicine have developed artificial interference RNA (aiRNA). aiRNA is a patented chimeric RNAi that combines the multi-target abilities of miRNAs and t…
— Disease indication – cancer, particularly lung, breast, colon, and prostate cancer or melanoma (cancers where chemerin is down-regulated at the tumor site)
Drug format – engineered fusion protein
Drug class – first in class
Research stage and Preliminary data
Target &ndash…
— Irf8 Delta32 mice have a CRISPR targetted deletion in the enhancer of the mouse Irf8 gene located at +32 kilobases from the Irf8 gene promoter. This deletion removes the binding site for the Jun/Batf3/Irf8 complex and results in a complete and permanent elimination of the development of the cDC1 lin…
— Technology Description
Researchers in Prof. Jeffrey Henderson’s laboratory have discovered a drug target and a class of small molecule candidates that could be used to selectively prevent pathogenic enterobacteria from causing diseases such as urinary tract infections (UTIs).
Currently, UTI…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
